Pirtobrutinib bulk supplier for pharma manufacturers

Pirtobrutinib 50mg, 100mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 50mg, 100mg

Reference Brands: Jaypirca(USA/EU)

Pirtobrutinib is a highly selective, non-covalent BTK inhibitor designed to overcome resistance to earlier BTK inhibitors. It is used in the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma. By reversibly inhibiting BTK, it blocks signaling required for cancer cell survival and proliferation.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Pirtobrutinib? List it or send an offer →

Product Description:

Pirtobrutinib inhibits Bruton's tyrosine kinase without forming a covalent bond to it. That distinction is the whole point. The established BTK inhibitors attach permanently to a cysteine residue at position 481, and the commonest route to resistance is a mutation at exactly that site, which leaves the enzyme functional but the drug unable to attach. A non-covalent inhibitor binds elsewhere and continues to work in those tumours.

It is used for relapsed or refractory chronic lymphocytic leukaemia, small lymphocytic lymphoma and mantle cell lymphoma in patients who have already received a covalent BTK inhibitor — a group that previously had few options and poor outcomes. Its selectivity also reduces the off-target effects that lead patients to stop the older drugs, with less atrial fibrillation and bleeding, although both still occur. Infection, neutropenia, fatigue, bruising and diarrhoea are reported.

Sourcing notes. Originator product, on patent, approved in a limited set of territories — confirm registration before quoting. Two tablet strengths support dose reduction. Demand follows the installed base of earlier BTK inhibitor use, so it concentrates in markets where those have been available for several years. Room temperature.

How Pirtobrutinib is supplied today, and licensing ahead of patent expiry

Pirtobrutinib is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Pirtobrutinib, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Pirtobrutinib supply →

Back to Listing

Frequently Asked Questions

Pirtobrutinib is used for the treatment of relapsed or refractory mantle cell lymphoma (MCL) and certain previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It helps inhibit cancer cell growth by targeting the BTK pathway.

Pirtobrutinib is made from a highly selective, non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor designed to target both wild-type and resistant BTK mutations.

The trade name is Jaypirca.

Jaypirca is manufactured by Eli Lilly and Company.

The generic name is Pirtobrutinib.

The brand name is Jaypirca.

It is manufactured by Eli Lilly in its regulated production facilities in the United States and other global sites for international supply.

Jaypirca (Pirtobrutinib) is developed and sold by Eli Lilly. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.